Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis

Journal of Consulting and Clinical Psychology

Volumn 69, Issue 6, 2001, Pages 942-949

  Mohr, David C ^a,b,c   Boudewyn, Arne C ^b,d   Goodkin, Donald E ^b   Bostrom, Alan ^b   Epstein, Lucy ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SERTRALINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; DEPRESSION; DRUG EFFICACY; FEMALE; FOLLOW UP; GROUP THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0035214749     PISSN: 0022006X     EISSN: None     Source Type: Journal    
DOI: 10.1037/0022-006X.69.6.942     Document Type: Article

References (78)

1. A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis
2. Revised estimate of the prevalence of multiple sclerosis in the United States
3. Current pharmacologic treatment of multiple sclerosis symptoms
4. Prediction of psychological adjustment to multiple sclerosis
5. Problem solving by patients with multiple sclerosis: Comparison of performance on the WI and CA Card Sorting Tests
6. An inventory for measuring depression
7. Diagnostic assessment of depression in the medically ill
8. Group psychotherapy: Benefits in multiple sclerosis
9. Stress management for multiple sclerosis patients
10. Disease activity and emotional state in multiple sclerosis
11. Counterbalancing patient demands with evidence: Results from a pan-Canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus
12. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis
13. Efficacy of stress-inoculation training in coping with multiple sclerosis
14. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis
15. Comparative effects of cognitive-behavioral and brief psychodynamic psychotherapies for depressed family caregivers
16. Depression, cognitive impairment and social stress in multiple sclerosis
17. The natural history of multiple sclerosis
18. Correlates of quality of life among persons with multiple sclerosis
19. A rating scale for depression
20. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care
21. Methods for defining and determining the clinical significance of treatment effects: Description, application, and alternatives
22. Mood disorder and multiple sclerosis
23. The Longitudinal Interval Follow-Up Evaluation: A comprehensive method for assessing outcome in prospective longitudinal studies
24. Normative comparisons for the evaluations of clinical significance
25. Depression in medically ill hospitalized older adults: Prevalence, characteristics, and course of symptoms according to six diagnostic schemes
26. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
27. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis
28. Defining the clinical course of multiple sclerosis: Results of an international survey
29. Boston Naming Test: Shortened versions for use in Alzheimer's disease
30. The effects of imagery on attitudes and moods in multiple sclerosis patients
31. Psychotherapy for people with multiple sclerosis
32. Depression in multiple sclerosis
33. Multiple sclerosis: Empirical literature for the clinical health psychologist
34. Multiple sclerosis
35. Treatment of depression in multiple sclerosis: Review and meta-analysis
36. Depression, coping, and level of neurological impairment in multiple sclerosis
37. Identification of Beck Depression Inventory items related to multiple sclerosis
38. Treatment of depression improves adherence to interferon beta-lb therapy for multiple sclerosis
39. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment
40. Side effect profile and compliance in the treatment of multiple sclerosis with interferon beta-1a
41. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis
42. Course of depression during the initiation of interferon beta-1a for multiple sclerosis
43. Adjustment to multiple sclerosis: Application of a stress and coping model
44. The role of coping in adjustment to multiple sclerosis-related adaptive demands
45. Disability and depression in rheumatoid arthritis
46. New diagnostic criteria for multiple sclerosis
47. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis
48. Structural brain correlates of emotional disorder in multiple sclerosis
49. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction
50. Cause of death in patients attending multiple sclerosis clinics
51. Symptom management in multiple sclerosis
52. Depressive episodes in patients with multiple sclerosis
53. Antidepressant pharmacotherapy of depression associated with multiple sclerosis
54. Increased depression in multiple sclerosis: A meta-analysis
55. Characterization of major depression symptoms in multiple sclerosis patients
56. Group support for patients with metastatic cancer: A randomized prospective outcome study
57. Group psychotherapy for recently diagnosed breast cancer patients: A multicenter study
58. Group therapy for chronic illness: A multidiagnosis group
59. An investigation into some psychiatric aspects of multiple sclerosis
60. Outcome definitions and predictors in depression
61. Multiple sclerosis: Symptomatic treatment
62. The cognitive therapy scale: Psychometric properties
63. A meta-analysis of outcome studies comparing bona fide psychotherapies: Empirically, "All must have prizes."
64. A structured interview version of the Hamilton Rating Scale for Depression: Reliability and validity
65. Depression as a major symptom of multiple sclerosis
66. What does the BDI measure in chronic pain?
67. A comparative analysis of coping behaviors in persons with multiple sclerosis or a spinal cord injury